福森药业(01652)：1.1类中药创新药“SY 617”临床试验申请获得受理

智通财经07-12

智通财经APP讯，福森药业(01652)发布公告，集团全资附属公司嘉亨(珠海横琴)医药科技有限公司已就所研发的“SY617”向中国国家药品监督管理局提交临床试验申请并获受理。SY617的功能主治为疏风解毒、清瘟除湿，用于流行性感冒辨证为风热夹湿证的治疗，症见发热、头重如裹、咽痛、恶风、咳嗽、肢体酸痛、胸闷、脘痞、舌质红，苔白腻或黄腻、脉濡或滑或浮数。据米内网数据显示，2022年唿吸系统疾病用药...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450585100?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-12 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2450585100","market":"us","top_or_hot":-1,"title":"福森药业(01652)：1.1类中药创新药“SY 617”临床试验申请获得受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，福森药业(01652)发布公告，集团全资附属公司嘉亨(珠海横琴)医药科技有限公司已就所研发的“SY617”向中国国家药品监督管理局提交临床试验申请并获受理。SY617的功能主治为疏风解毒、清瘟除湿，用于流行性感冒辨证为风热夹湿证的治疗，症见发热、头重如裹、咽痛、恶风、咳嗽、肢体酸痛、胸闷、脘痞、舌质红，苔白腻或黄腻、脉濡或滑或浮数。据米内网数据显示，2022年唿吸系统疾病用药...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1150248.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>福森药业(01652)：1.1类中药创新药“SY 617”临床试验申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n福森药业(01652)：1.1类中药创新药“SY 617”临床试验申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-12 19:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1150248.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，福森药业(01652)发布公告，集团全资附属公司嘉亨(珠海横琴)医药科技有限公司已就所研发的“SY617”向中国国家药品监督管理局提交临床试验申请并获受理。SY617的功能主治为疏风解毒、清瘟除湿，用于流行性感冒辨证为风热夹湿证的治疗，症见发热、头重如裹、咽痛、恶风、咳嗽、肢体酸痛、胸闷、脘痞、舌质红，苔白腻或黄腻、脉濡或滑或浮数。据米内网数据显示，2022年唿吸系统疾病用药...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1150248.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06978","symbol_name":"永泰生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1150248.html","article_id":"2450585100","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450585100","pubTimestamp":1720782665,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，福森药业 发布公告，集团全资附属公司嘉亨医药科技有限公司已就所研发的“SY617”向中国国家药品监督管理局提交临床试验申请并获受理。本品属于1.1类处方组成符合中医药理论、具有人用经验的中药创新药。依据《中药注册管理专门规定》，SY617毋须进行I期临床试验。因此，其直接提出II期临床试验申请，目前已获中国国家药品监督管理局药品审评中心受理。SY617在治疗流行性感冒辨证为风热夹湿证等方面展现了非常有利的前景。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","06978":"永泰生物-B","BK1161":"生物科技","BK1191":"制药","BK4077":"互动媒体与服务","SY":"新氧","BK1574":"生物医药B类股","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","01652":"福森药业","03347":"泰格医药","BK4503":"景林资产持仓","BK4563":"昨日强势股"},"translate_title":"Fusen Pharmaceutical (01652): The application for clinical trial of Class 1.1 traditional Chinese medicine innovative drug \"SY 617\" was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"01652":1,"03347":1,"06978":1,"SY":1},"content_text":"智通财经APP讯，福森药业(01652)发布公告，集团全资附属公司嘉亨(珠海横琴)医药科技有限公司已就所研发的“SY617”向中国国家药品监督管理局提交临床试验申请并获受理。SY617的功能主治为疏风解毒、清瘟除湿，用于流行性感冒辨证为风热夹湿证的治疗，症见发热、头重如裹、咽痛、恶风、咳嗽、肢体酸痛、胸闷、脘痞、舌质红，苔白腻或黄腻、脉濡或滑或浮数。据米内网数据显示，2022年唿吸系统疾病用药中成药排名前叁分别是清热解毒类、止咳祛痰平喘用药和感冒用药，感冒用药中成药市场规模排在第叁位。2022年感冒用药中成药在医院渠道销售额约为85亿元，2023年上半年在医院渠道销售额超过45亿元。流行性感冒(简称流感)是一种由流感病毒引起的，有高度传染性、高发病率、高变异性、反复感染的急性唿吸道疾病。目前国际指南推荐及中国上市的主流药物神经氨酸酶抑制剂具有一定的局限性，且可能产生耐药性，迫切需要寻找其他有效的治疗措施。中医药在消除患者流感症状、提高患者抗病康复能力以及防止并发症方面有着独特优势。SY617是成都中医药大学附属医院(四川省中医医院)两个具有多年以上使用历史的院内制剂，在中医药理论指导下，经过有效加合而开展转化研究，曾入选四川省中医药管理局中医药重大科技项目。本品属于1.1类处方组成符合中医药理论、具有人用经验的中药创新药。依据《中药注册管理专门规定》，SY617毋须进行I期临床试验。因此，其直接提出II期临床试验申请，目前已获中国国家药品监督管理局药品审评中心受理(受理号：CXZL2400038)。SY617在治疗流行性感冒辨证为风热夹湿证等方面展现了非常有利的前景。SY617是继双黄连口服液和双黄连注射液之后的又一款重磅中药抗感产品，进一步丰富了集团在抗感中成药治疗领域的产品管线。该产品上市后将会为流行性感冒辨证为风热夹湿证患者提供更多的治疗选择。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450585100"}